Amgen, AstraZeneca's tezepelumab is looking for a slice of blockbuster asthma market dominated by Sanofi's Dupixent

After seeking approval for tezepelumab in severe asthma on Monday, Amgen and collaborator AstraZeneca are laying all their cards on the table with hopes of eating up portions of the market left behind by Sanofi’s Dupixent.